UOC
CGON icon

UBS O'Connor’s CG Oncology CGON Stock Holding History

UBS O'Connor’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,000
Closed -$676K – 319
2025
Q2 		$676K Buy
+26,000
New +$627K 0.02% 255
2025
Q1 		– Sell
-12,834
Closed -$368K – 363
2024
Q4 		$368K Buy
12,834
+1,810
+16% +$61.9K 0.01% 303
2024
Q3 		$416K Buy
11,024
+1,024
+10% +$35.9K 0.01% 354
2024
Q2 		$316K Buy
+10,000
New +$347K 0.01% 395

Other funds holding CGON

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS O'Connor's CGON Position: Q3 2025 in Review

UBS O'Connor sold out of CG Oncology (CGON) in Q3 2025, closing a stake of 26,000 shares — an estimated $676K sold.

UBS O'Connor first reported a position in CGON in Q2 2024 and held it in 4 quarters. The position peaked at $676K in Q2 2025. 176 funds tracked by Wall St. Rank hold CGON as of Q3 2025.

  • UBS O'Connor reported no remaining CG Oncology position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 26,000 CG Oncology shares in Q3 2025, an estimated $676K.
  • UBS O'Connor first reported a position in CG Oncology in Q2 2024 and held it in 4 quarters.
  • UBS O'Connor's CG Oncology position peaked at $676K in Q2 2025.
  • 176 funds tracked by Wall St. Rank held CG Oncology as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.